Clinical Trial Update: Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating dasatinib combined with zoledronic acid for breast cancer with bone metastases; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Breast Cancer

Drugs mentioned

• DASATINIB (Dasatinib)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer, Bone Metastases | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-25